Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?

Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’

TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and COVID-19

Lung Cancer Considered - Episode XXV - Mar 16, 2020 Dr. Marty Edelman Speaks With IASLC President Dr. Tetsuya Mitsudomi

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr. Karen Kelly

An Interview with Dr. Federico Cappuzzo: Checkpoint Inhibitors Have Replaced Old Strategies